Sorafenib, a drug traditionally used to treat cancer, has shown promise as a macular degeneration treatment.
Most macular degeneration treatments concentrate on vascular endothelial grown factor inhibition and have become known as anti-VEGF treatments. Drugs such as Lucentis and Avastin have been traditional anti-VEGF macular degeneration treatments.
Other research in finding a macular degeneration treatment has considered platelet-derived growth factors (PDGF) and placenta growth facter (PLGF). Some research has shown these may impact the development of the eye disease macular degeneration.
Sorafenib is a cancer drug that blocks the action of VEGF and PDGF.
Studies have shown when human retinal pigment epithelial (RPE) cells were exposed to whiet light, light decreased the cell viability and increased both the expression and secretion of VEGF, PDGF and PLGF. When treated with sorafenib, these light induced effects were reduced significantly.
Traditionally a kidney and liver cancer drug, the investigators concluded that sorafenib has promisign properties that make a potential treatment for macular degeneration.